Clinical trials: Spleen Disorder
Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
This international multi-center, randomized, controlled, open-label study investigated the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (INN: rituximab, CJSC Biocad) versus MabThera® (INN: rituximab, F.
- Conditions
- Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
- Trial name
- NCT01701232
- Testing
- rituximab
- Where
- 62 sites in Colombia, India and 3 more
- Volunteers
- 174 people
- Sponsor
- Biocad
Leukemia, Lymphoma
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as fludarabine and pixantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00551239
- Testing
- rituximab, fludarabine phosphate, pixantrone dimaleate
- Where
- United States
- Sponsor
- CTI BioPharma
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01773187
- Testing
- Pacritinib, Best Available Therapy
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 327 people
- Sponsor
- CTI BioPharma
Myelofibrosis, Moderate Thrombocytopenia
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction…
- Conditions
- Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
- Trial name
- SENTRY-2 (NCT05980806)
- Testing
- Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib
- Where
- 70 sites in United States, Belgium and 17 more
- Volunteers
- 58 people
- Sponsor
- Karyopharm Therapeutics Inc
Thalassemia Major
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Patients with severe thalassemia (thalassemia major) present with severe anemia that required life-long transfusion therapy, spleen enlargement that led to increased transfusion requirement, and other serious complications as…
- Trial name
- NCT02049450
- Testing
- ruxolitinib
- Where
- 7 sites in Greece, Italy and 3 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma
Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
- Trial name
- NCT05544019
- Testing
- SGR-1505
- Where
- 36 sites in United States, France and 6 more
- Volunteers
- 98 people
- Sponsor
- Schrödinger, Inc.
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Chronic Fatigue Syndrome
Compound Ciwujia Granules Treat Chronic Fatigue Syndrome
To observe the improvement of Chalder scale score in patients with chronic fatigue syndrome treated by Compound Ciwujia Granules. Improvement =[(baseline score - post-treatment score)/baseline score]*100%
- Trial name
- NCT06245642
- Testing
- Compound Ciwujia Granules, Guipi Granules
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Heilongjiang Quanle Pharmaceutical Co., Ltd.
Aneurysm, Endoleak
Cera™ Vascular Plug System Post-Market Clinical Follow-Up
The objective of the study is to collect and evaluate clinical data on patients of the Lifetech Cera™ Vascular Plug System to: confirm the performance confirm the safety identify previously unknown side-effects monitor the…
- Conditions
- Aneurysm, Endoleak, Pulmonary Arteriovenous Malformation, Portal Hypertension
- Trial name
- NCT06099015
- Testing
- Cera™ Vascular Plug System
- Where
- 9 sites in Germany, Italy and 1 more
- Volunteers
- 132 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL).
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PACIFICA (NCT03165734)
- Testing
- Pacritinib, Physician's Choice medications
- Where
- 207 sites in United States, Australia and 22 more
- Volunteers
- 407 people
- Sponsor
- Swedish Orphan Biovitrum
Myelofibrosis (MF)
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger.
- Trial name
- TRANSFORM-2 (NCT04468984)
- Testing
- Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
- Where
- 229 sites in United States, Australia and 28 more
- Volunteers
- 330 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
ConsideRAte Study - Splenic Stimulation for RA
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and…
- Trial name
- NCT05003310
- Testing
- Active Stimulation, Baricitinib, Background Treatment
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 28 people
- Sponsor
- Galvani Bioelectronics
Gaucher Disease, Splenomegaly, Acid SphingoMyelinase Deficiency
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen
Primary Objective: To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g.
- Trial name
- OPPUS (NCT04845958)
- Where
- 40 sites in France
- Volunteers
- 60 people
- Sponsor
- Sanofi
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00025129
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Cirrhosis
Spleen Stiffness Measurement With FibroScan
FibroScan® (Echosens, Paris, France) is an active non implantable medical device marketed in Europe since December 2003 and is currently used in many countries.
- Trial name
- NCT02180113
- Testing
- Fibroscan® examination
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Echosens
Lymphoma
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma.
- Trial name
- NCT00003338
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Leukemia, Lymphoma
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Trial name
- NCT00003056
- Testing
- cyclosporine, cyclosporine and methotrexate
- Where
- 13 sites in United States, Australia
- Volunteers
- 105 people
- Sponsor
- Baxalta now part of Shire
Cardiac Disorder, Hepatic Disorder
Kosmos Anatomical Object Labeling and View Identification Pivotal Study
This is a multi-site, multi-group study that obtained two sets of ultrasound scans from all enrolled participants. Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers.
- Conditions
- Cardiac Disorder, Hepatic Disorder, Spleen Disorder, Kidney Disorder
- Trial name
- NCT06468787
- Testing
- Kosmos Anatomical Object Labeling and View Identification Algorithms
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- EchoNous Inc.
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics